Cyclophosphamide in lupus nephritis: a controlled trial.
about
Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosusTreatment for lupus nephritisCyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosusTreatment for lupus nephritisTreatment of patients with systemic lupus erythematosus including nephritis with chlorambucilPediatric lupus nephritis: Management updateThe epidemiology of systemic lupus erythematosus: 1950-1990 conceptual advances and the ARAMIS data banks.Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseasesRecent advances in the immunopathogenesis of systemic lupus erythematosus.Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus.Successful treatment of autoimmune disease in (NZB/NZW)F1 female mice by using fractionated total lymphoid irradiation.Problems with immunosuppressive agents in renal diseaseCombination treatment in autoimmune diseases: systemic lupus erythematosus.Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?Challenges in bringing the bench to bedside in drug development for SLE.Emergence of targeted immune therapies for systemic lupus.Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice.Success using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria.Theoretical and experimental approaches to generalized autoimmunity.Cytotoxic agents in childhood glomerulonephritis.Comparison of chlorambucil, azathioprine or cyclophosphamide combined with corticosteroids in the treatment of lupus nephritis.Cyclophosphamide protection in NZB/NZW disease. Mechanisms and therapeutic regimens.Reactivities of systemic lupus erythematosus sera with cellular and virus antigen preparations.Genetic and immune aspects of systemic lupus erythematosus.The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease.Cyclophosphamide treatment in polyarteritis nodosa.Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis.Treatment of active chronic hepatitis with cyclophosphamideOral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid.Efficacy of immunosuppressive drugs in rheumatic diseases.Glomerulonephritis--1974.Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: a case-control study.Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody.A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis.Comparison of therapeutic and immunosuppressive effects of azathioprine, prednisolone and combined therapy in NZP-NZW mice.Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.Favorable outcome in diffuse proliferative glomerulonephritis of systemic lupus erythematosus.The fourth component of complement in the cerebrospinal fluid in systemic Lupus erythematosus.Vasculitides throughout history and their clinical treatment today.
P2860
Q24200954-324FAB3A-0AA5-4276-A59B-481A637C4C0AQ24202572-C3B6C5A7-4E4C-4BF8-AB4C-EEE86F0C27B2Q24246092-AA9FB763-7953-41DF-86DD-D43EFEAC20B8Q24247408-EEB74584-9CB1-42BC-8355-16758D291DE2Q28363829-78F2F254-30DB-4985-889D-DDACCB0DDA09Q28660110-E84EE4B4-E77C-4B9F-8455-8606D3C24E97Q30661190-633D7106-C57F-40A8-A7F7-E55D7841E4B4Q33553829-E0E6180B-59CF-4B70-8687-5328C08A0CC5Q33824546-88581656-3AFB-44BD-908D-000B45E11102Q33978636-AF3EA748-6EA5-43AA-9004-E643F4D962D5Q34038685-C64C0234-B136-464D-8935-31FA1302A384Q34302895-2E087D29-F90C-47C0-85AE-39B1B1DDF7AFQ34309764-D81CA7CD-30DF-4EA6-8449-A2B02A7C8087Q35824537-ADF8E915-8537-41B8-BEFA-DBFA5C523B34Q35968394-51ABBAF3-1115-41A7-8AAE-23C6EBE70735Q36066014-F1C5FBDE-623E-475E-9F32-2F85EEEB7AA1Q36302245-445F3AF8-F47A-450C-A3C0-FD16C0ED8784Q36903043-E51108D2-7BD3-4F57-BD6A-B1F8DE46C389Q37150681-219F550E-E8DA-4B04-BADB-F5B56A60A293Q37783216-E59048D0-A9CF-4F1F-B184-1340BAC4ABF0Q39508879-2343BE18-4625-4A7F-A1C2-EB78AC3E70D2Q39536979-4C2E9F49-BDA7-401A-B31B-B9C168619FB0Q39761788-2F0CA895-9192-43A6-8A95-78933D10657DQ40202542-8395E47D-95AA-46A7-9848-CCCC80C65676Q40218886-BFBD113E-DCC9-4069-A6BE-19C723CCC097Q40479239-D4058651-6AF5-4096-86FC-E23181A70902Q40807892-00B65DA9-5B01-48DD-90FC-1943CEB472EBQ40912817-9C17856B-8E83-4873-A6E4-BE463ECB1F7EQ41238343-F868DEE2-7958-4C8C-B461-51DB9BD38F37Q43789787-AC684F17-FE57-4162-BA32-1E9E1751E9ECQ43840658-65D09B40-8E4D-4104-A07C-B16F7CD04666Q44009488-D39A9403-C902-4DF3-8B32-04B0E188B3CCQ44112212-CA9D1D43-A218-4D48-8B66-7B2EAA7BC6DAQ44360884-4F30CBF7-87D5-49CA-94CA-D7F412D5E893Q44482867-E7B01A9A-3C64-4EFD-9ECE-CA47E90E7223Q44505272-BD52547C-13C7-465D-97C7-A68345703EEBQ44973876-3AA4D7B7-8726-4FEC-885D-C19837F1A31BQ45245883-F1AC170D-A2DB-4138-BA1A-9BBBA5AE524AQ47981964-D412B870-0B9A-4D12-848E-62A79828CCB0Q48594996-9F3E3C03-ECA7-4A57-BC24-5E040EFE9996
P2860
Cyclophosphamide in lupus nephritis: a controlled trial.
description
1971 nî lūn-bûn
@nan
1971 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1971 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1971年の論文
@ja
1971年論文
@yue
1971年論文
@zh-hant
1971年論文
@zh-hk
1971年論文
@zh-mo
1971年論文
@zh-tw
1971年论文
@wuu
name
Cyclophosphamide in lupus nephritis: a controlled trial.
@ast
Cyclophosphamide in lupus nephritis: a controlled trial.
@en
Cyclophosphamide in lupus nephritis: a controlled trial.
@nl
type
label
Cyclophosphamide in lupus nephritis: a controlled trial.
@ast
Cyclophosphamide in lupus nephritis: a controlled trial.
@en
Cyclophosphamide in lupus nephritis: a controlled trial.
@nl
prefLabel
Cyclophosphamide in lupus nephritis: a controlled trial.
@ast
Cyclophosphamide in lupus nephritis: a controlled trial.
@en
Cyclophosphamide in lupus nephritis: a controlled trial.
@nl
P2093
P1476
Cyclophosphamide in lupus nephritis: a controlled trial.
@en
P2093
Kaltreider HB
Staples PJ
Steinberg AD
P304
P356
10.7326/0003-4819-75-2-165
P407
P577
1971-08-01T00:00:00Z